Literature DB >> 17968950

Overexpression of human decoy receptor 3 in mice results in a systemic lupus erythematosus-like syndrome.

Bing Han1, Paul A Moore, Jiangping Wu, Hongyu Luo.   

Abstract

OBJECTIVE: Decoy receptor 3 (DcR3), a tumor necrosis factor receptor family member, is a secreted protein that can enhance cell survival by interfering with multiple apoptosis pathways. This study was undertaken to investigate the role of DcR3 in the pathogenesis of autoimmune disease.
METHODS: We generated transgenic mice with actin promoter-driven expression of human DcR3 and investigated the development of autoimmune disease in these mice.
RESULTS: T cell immune responses were compromised in young DcR3-transgenic mice. Beyond 5-6 months of age, transgenic mice developed a systemic lupus erythematosus (SLE)-like syndrome, with numerous features of the disease. They produced autoantibodies against double-stranded DNA. Their kidneys showed pathologic changes indicative of glomerular nephritis and IgG and C3 deposition, and proteinuria, leukocyturia, and hematuria, were evident. Aged transgenic mice also developed skin lesions and lymphocyte infiltration in the liver, and exhibited leukopenia, anemia, and thrombocytopenia. The SLE-like syndrome penetrance in DcR3-transgenic mice was sex associated, occurring in approximately 60% of females versus 20% of males. Exogenous recombinant DcR3 or endogenous DcR3 produced by transgenic T cells effectively protected T cells against activation-induced apoptosis in vitro. Probably as a consequence of this, CD4 cells with a phenotype of previous activation were increased in the peripheral blood of transgenic mice beyond 6 months of age.
CONCLUSION: These results show that DcR3 overexpression could lead to an SLE-like syndrome in mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968950     DOI: 10.1002/art.22978

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Pno1 tissue-specific expression and its functions related to the immune responses and proteasome activities.

Authors:  Xuehai Wang; Tao Wu; Yan Hu; Martin Marcinkiewicz; Shijie Qi; Hector Valderrama-Carvajal; Hongyu Luo; Jiangping Wu
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

Review 2.  Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes?

Authors:  Giuliana Guggino; Anna Rita Giardina; Francesco Ciccia; Giovanni Triolo; Francesco Dieli; Guido Sireci
Journal:  Clin Dev Immunol       Date:  2011-08-16

3.  To investigate the necessity of STRA6 upregulation in T cells during T cell immune responses.

Authors:  Rafik Terra; Xuehai Wang; Yan Hu; Tania Charpentier; Alain Lamarre; Ming Zhong; Hui Sun; Jianning Mao; Shijie Qi; Hongyu Luo; Jiangping Wu
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

Review 4.  The role of TL1A and DR3 in autoimmune and inflammatory diseases.

Authors:  Yoshihiro Aiba; Minoru Nakamura
Journal:  Mediators Inflamm       Date:  2013-12-21       Impact factor: 4.711

5.  Armc5 deletion causes developmental defects and compromises T-cell immune responses.

Authors:  Yan Hu; Linjiang Lao; Jianning Mao; Wei Jin; Hongyu Luo; Tania Charpentier; Shijie Qi; Junzheng Peng; Bing Hu; Mieczyslaw Martin Marcinkiewicz; Alain Lamarre; Jiangping Wu
Journal:  Nat Commun       Date:  2017-02-07       Impact factor: 14.919

6.  The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.

Authors:  James E McLaren; Claudia J Calder; Brian P McSharry; Keith Sexton; Rebecca C Salter; Nishi N Singh; Gavin W G Wilkinson; Eddie C Y Wang; Dipak P Ramji
Journal:  J Immunol       Date:  2010-04-21       Impact factor: 5.422

7.  Investigation of tissue-specific expression and functions of MLF1-IP during development and in the immune system.

Authors:  Xuehai Wang; Martin Marcinkiewicz; Yaned Gatain; Maxime Bouchard; Jianning Mao; Michel Tremblay; Noriko Uetani; Silva Hanissian; Shijie Qi; Jiangping Wu; Hongyu Luo
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.